Introduction：Basic information about CAS 1445385-02-3|ALS-8176, including its chemical name, molecular formula, synonyms, physicochemical properties, and safety information, etc.
| Common Name | ALS-8176 |
|---|
| CAS Number | 1445385-02-3 | Molecular Weight | 433.859 |
|---|
| Density | 1.4±0.1 g/cm3 | Boiling Point | 533.5±60.0 °C at 760 mmHg |
|---|
| Molecular Formula | C18H25ClFN3O6 | Melting Point | / |
|---|
| MSDS | / | Flash Point | 276.4±32.9 °C |
|---|
Names
| Name | ALS-8176 |
|---|
| Synonym | More Synonyms |
|---|
ALS-8176 BiologicalActivity
| Description | Lumicitabine (ALS-008176) is an inhibitor of the respiratory syncytial virus (RSV) polymerase. |
|---|
| Related Catalog | Signaling Pathways >>Anti-infection >>RSVResearch Areas >>Infection |
|---|
| In Vitro | Lumicitabine is an orally bioavailable prodrug of the novel RSV replication inhibitor ALS-008112, a cytidine nucleoside analogue[1]. |
|---|
| In Vivo | Lumicitabine demonstrates excellent anti-RSV efficacy and safety in a phase 2 clinical RSV challenge study. It exhibits good oral bioavailability and a high level of 2c-TP in vivo. Lumicitabine has excellent stability profiles in formulations (>24 h storage stability in 0.5% methylcellulose aqueous formulation at rt) and simulats gastric and intestinal fluids (half-life >2 h). Its solubility is adequate to support oral administration in solutions with relatively low percentage of organic solvent and in aqueous suspensions. High levels of NMP and NTP are obtained following oral administration of Lumicitabine to monkeys[2]. In an adult human challenge study, Lumicitabine has shown efficacy against RSV infection[1]. |
|---|
| Animal Admin | Rats: Lumicitabine are formulated as solutions in PEG400-based vehicles. Pharmacokinetic studies are conducted at 5 mg/kg and for oral PK studies the prodrugs are administered at 5 mg/kg parent nucleoside equivalent doses. Blood samples are typically collected at various time points up to 24 h post dose for rat[2]. Monkeys: Lumicitabine are formulated as solutions in PEG400-based vehicles. Pharmacokinetic studies are conducted at 5 mg/kg and for oral PK studies the prodrugs are administered at 5 mg/kg parent nucleoside equivalent doses. Blood samples are typically collected at various time points up to 12 h post dose for Monkeys[2]. |
|---|
| References | [1]. DeVincenzo JP, et al. Activity of Oral ALS-008176 in a Respiratory Syncytial Virus Challenge Study. N Engl J Med. 2015 Nov 19;373(21):2048-58. [2]. Wang G, et al. Discovery of 4'-chloromethyl-2'-deoxy-3',5'-di-O-isobutyryl-2'-fluorocytidine (ALS-8176), a first-in-class RSV polymerase inhibitor for treatment of human respiratory syncytial virus infection. J Med Chem. 2015 Feb 26;58(4):1862-78. |
|---|
Chemical & Physical Properties
| Density | 1.4±0.1 g/cm3 |
|---|
| Boiling Point | 533.5±60.0 °C at 760 mmHg |
|---|
| Molecular Formula | C18H25ClFN3O6 |
|---|
| Molecular Weight | 433.859 |
|---|
| Flash Point | 276.4±32.9 °C |
|---|
| Exact Mass | 433.141602 |
|---|
| LogP | 2.31 |
|---|
| Vapour Pressure | 0.0±1.4 mmHg at 25°C |
|---|
| Index of Refraction | 1.577 |
|---|
| InChIKey | MJVKYGMNSQJLIN-KYZVSKTDSA-N |
|---|
| SMILES | CC(C)C(=O)OCC1(CCl)OC(n2ccc(N)nc2=O)C(F)C1OC(=O)C(C)C |
|---|
Synonyms
| ALS-8176 |
| 4-Amino-1-{5-chloro-2,5-dideoxy-2-fluoro-3-O-isobutyryl-4-[(isobutyryloxy)methyl]-α-L-lyxofuranosyl}-2(1H)-pyrimidinone |
| Lumicitabine |
| 2(1H)-Pyrimidinone, 4-amino-1-[5-chloro-2,5-dideoxy-2-fluoro-4-C-[(2-methyl-1-oxopropoxy)methyl]-3-O-(2-methyl-1-oxopropyl)-α-L-lyxofuranosyl]- |
| BNW5PQ52G1 |
| 4'-C-(chloromethyl)-2'-deoxy-2'-fluorocytidine 3',5'-bis(2-methylpropanoate) |
| UNII:BNW5PQ52G1 |
